Comparable strategies needed to evaluate human papillomavirus vaccine efficiency across Europe.
Soldan
K
K
Health Protection Agency Centre for Infections, London, United Kingdom. kate.soldan@hpa.org.uk
Dillner
J
J
D000293:Adolescent; D000328:Adult; D052685:Alphapapillomavirus / Q000145:classification / Q000276:immunology; D002648:Child; D005060:Europe / Q000453:epidemiology; D005260:Female; D014943:Global Health; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D007391:International Cooperation; D008297:Male; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines; D011159:Population Surveillance; D015397:Program Evaluation / Q000592:standards; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control; D014611:Vaccination / Q000706:statistics & numerical data*; D014944:World Health Organization
D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18